RFA-NS-24-031: BRAIN Initiative Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18)

RFA-NS-24-031: BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18)

This NIH NOFO is designed for teams building the next generation of central nervous system (CNS) recording and modulation technologies before human studies. It supports technical feasibility and translational work from proof of concept to a path toward first-in-human development. The program is explicitly not a clinical trial pathway; it is focused on device and system development, validation, and de-risking work that can be reviewed in a preclinical setting.

The opportunity is part of the BRAIN Initiative ecosystem and has recurring annual submission windows. As of this review, key dates include an application due date of January 28, 2027 for the 2027 cycle, with earlier 2026 and 2025 rounds already listed in the same NOFO framework. The NOFO indicates a recurring review flow with scientific peer review, advisory review, and project starts in a timeline pattern tied to those cycles.

Key opportunity details

What this opportunity is and why it is specific

This is not a broad, open-ended research grant. It is not asking for “any” neuroscience work. It is asking for a narrow class of projects: preclinical hardware/device/software systems for recording and modulation in the human CNS that have a plausible and measurable path to human applicability within about five years.

The opportunity explicitly prioritizes projects that can show:

• Clear proof-of-concept value (not a full mature product)
• A technology-development plan that bridges from feasibility to translational readiness
• Design-control thinking and a documented pathway toward regulatory and engineering maturity
• Practical commercialization-oriented decisions such as packaging, firmware validation, or stakeholder/user validation

This specificity is important because the review language repeatedly rewards proposals that define what the device does, why it is better than alternatives, and how it could become clinically relevant even when clinical work itself is outside the scope.

A recurring misconception is treating this as a general neuro-engineering exploration grant. The NOFO language is much stricter: it wants proof-of-concept and viability work that creates a credible path to human use and de-risks translation. If your project is still at a conceptual curiosity stage with no measurable milestones, no clear anatomical target, and no plan for regulatory or design maturation, it is vulnerable to being judged weak.

Who should apply: best fit and practical exclusion points

This NOFO is most suitable for teams that:

• Are already in translational biomedical engineering, device development, control systems, signal acquisition, or neurophysiology
• Can specify a CNS target and explain why your technology materially improves on existing tools
• Have access to engineering plus biological or clinical collaborators who can stress-test design decisions
• Can handle cross-functional work: design, manufacturing interface, validation planning, regulatory interactions, and commercialization planning

It is not ideal for teams that only have a hypothesis and do not yet have an engineering artifact plan or a route to device validation.

The nonresponsive criteria are also meaningful:

• Clinical trials are explicitly disallowed
• Projects limited to peripheral nervous system targets only (outside CNS treatment/diagnosis or CNS knowledge goals) can be removed by reviewers
• Delayed-onset studies are not allowed
• Missing required attachments can lead to automatic non-consideration

Eligibility profile in concrete terms

According to the NOFO, eligible applicant entities are broad but U.S.-anchored. The core list includes higher education, nonprofits, for-profits (including small businesses), local and federal government entities, and some additional U.S. organization types. In contrast, non-U.S. entities are not eligible, and non-domestic components of U.S. organizations are also not eligible.

If you work with an international partner, frame them as collaborators only where allowed by NIH component rules; avoid creating an ineligible primary-subaward structure that puts your application outside eligibility.

Funding and budget interpretation

The document gives two useful budget anchors:

1. The full opportunity has an estimated total of about $8M aimed at 5–7 awards.
2. Budgets are not globally capped, but NIH guidance says annual budgets should usually not exceed $750,000 in direct costs.

For applicants, this means you should:

• Budget by real execution needs instead of inflationary optimism
• Allocate carefully to the stages you can credibly deliver in a 3-year period
• Treat post-award commercialization plans as strategic, not cost-heavy boilerplate

There is no expectation of a minimum award amount in the NOFO, so avoid over-designing for scale without scientific justification. Reviewers and program staff often score plans more favorably when budget scope is clearly tied to technical milestones.

What the review process evaluates

Peer review follows the NIH framework and then applies NOFO-specific criteria. The central themes are:

1) Significance

Reviewers first ask: does this project solve a meaningful technical barrier that matters for CNS diagnosis or treatment, and does it improve over existing approaches?

NIH explicitly highlights significance factors like:

• Comparative advantage versus commercial or existing options
• Rationale for chosen anatomical target
• Clinical relevance for CNS-focused needs

2) Investigator team

NIH evaluates whether the team is genuinely multidisciplinary and whether leadership has the right balance of domains. The review language asks for proof of role clarity and execution capacity, including the Team Management Plan. This is a direct signal that single-PI paperscience narratives without team governance are often less compelling than cross-role execution structures.

3) Innovation

This NOFO is competitive for teams with a concrete device-level innovation path, not simply broad exploratory claims. To score well, your concept should show novel design, clear expected upside, and evidence that the technology could be differentiated in a crowded field.

4) Approach

Approach scoring is often where technical proposals fail. Your work should include:

• A realistic staged roadmap
• Milestones and measurable decision gates
• Design criteria and stakeholder-informed needs mapping
• Risks and alternatives for each high-risk branch
• A post-award transition path or next-stage continuity plan

5) Environment

Infrastructure and partnerships matter. Reviewers look for translational depth, including whether you have the appropriate expertise in regulatory, manufacturing, and commercialization pathways that can carry a preclinical technology toward human use.

Additional review points

The NOFO also has additional consideration areas: timeline feasibility, team management quality, resource sharing expectations, and budget rationale. These are often decisive near the funding line because strong science can still lose ground if execution planning appears weak.

Application process and required package (where people usually get stuck)

1. Register first, then build backward

Registration timing is a hard gate. The NOFO stresses that incomplete registrations are a known failure point and do not justify late submission excuses.

You need, at minimum:

• SAM (and NCAGE/UEI steps as applicable)
• eRA Commons account for organization, plus PI roles configured
• Grants.gov registration

Start this early because eRA/SAM flow can take weeks.

2. Use official submission route only

The NOFO accepts only NIH-supported submission channels:

• NIH ASSIST
• institutional system-to-system to Grants.gov and eRA Commons
• Grants.gov Workspace

Paper applications are not accepted.

3. Build required attachments (all of them)

The NOFO identifies required and heavily weighted attachments that can make or break compliance:

• Gantt chart (1-page max)
• Needs Assessment (3-page max)
• Intellectual Property Strategy (3-page max)
• Team Management Plan
• Current-State-of-the-Art statement

Most applications that miss one of these required components can be treated as nonresponsive. The safest practice is to prepare this as a pre- submission compliance packet, then import into the SF424 forms only after all attachments are finalized.

4. Respect page limits and structure

NIH review is strict on page limits and attachment naming. Every attachment should be prepared with explicit file naming and exact placement expected in the forms. Do not substitute narrative prose for required attachments.

5. Show a realistic pathway to human relevance

Even though clinical trials are not funded, you must show a credible preclinical-to-human pathway. The NOFO language repeatedly references design controls, quality systems, regulatory interface, and evidence that your concept can move toward first-in-human readiness if funded successfully.

6. Manage dates against recurring cycle

For 2027 applicants, the due date is Jan 28, 2027 (local time of applicant organization at 5:00 PM). The NOFO also asks the standard practice of early submission to allow changes for technical warnings before the hard deadline. The same practical rule applies to all NIH cycles.

Preparation strategy for a stronger submission

A competitive application usually follows this sequence:

1. Technical premise lock: Define one core mechanism, one target class, one measurable benchmark suite.
2. Scope reduction: Remove optional ideas that do not strengthen the proof-of-concept path.
3. Dependency map: List what hardware tools, animal models, fabrication routes, and regulatory inputs you need.
4. Milestone architecture: Build a timeline from month 1 to month 36 with contingency branches.
5. Risk register: Explicitly list failure risks and mitigation for each step.
6. Reviewer narrative pass: Convert each criterion into one dedicated evidence block (Significance, Investigator, Innovation, Approach, Environment, budget and timeline).

Practical review lens: what reviewers expect in each section

• For Significance, anchor to specific CNS barriers, not broad neuroscience ambition.
• For Innovation, compare to existing technologies and demonstrate why your method can outperform commercial alternatives.
• For Approach, keep the plan testable and quantitative.
• For Team Management, demonstrate roles and governance for interdisciplinary execution.
• For Approach to commercialization, explain the interface with technology transfer and IP stewardship without overselling.

Common mistakes that cost opportunities

Common fail points we see in preclinical device NOFOs:

• Missing required attachments or wrong page limits
• Weak anatomical definition (no clear CNS target)
• Claims about clinical outcomes without preclinical grounding
• No concrete design-to-regulatory roadmap
• Underdeveloped IP/commercialization planning when translational pathway is central
• Budgets disconnected from milestones
• Assuming foreign collaborators automatically satisfy domestic-entity rules

Most nonresponsive actions are often administrative, not scientific. If the package is incomplete or not aligned with NOFO requirements, reviewers may never assess your science.

Candidate checklist before hitting submit

• Confirm registration in SAM/eRA Commons/Grants.gov and role configuration
• Confirm NIH entity and PI credentials are correctly linked
• Draft and internally review all required attachments
• Validate that clinical trials are not proposed
• Verify no prohibited activities (peripheral-only technology focus, delayed-onset studies)
• Reconcile budget with annual DC/total scope and 3-year max duration
• Ensure Team Management Plan is explicit and realistic
• Confirm letter of intent deadline is tracked (optional but recommended)
• Test submission path in advance and plan for correction window before deadline

FAQ

Is this restricted to only one organization type?

No. It is broad among U.S. entities (universities, nonprofits, for-profits, governments, etc.) but excludes non-U.S. entities as eligible direct applicants.

Is there a cost-sharing requirement?

The NOFO does not require cost sharing for this opportunity.

Can foreign experts participate?

Collaboration can still be possible in certain roles, but foreign organizations themselves are not eligible and foreign components of U.S. organizations are not eligible as applicants. Structure partnerships carefully and keep eligibility language aligned.

Can this support full commercialization?

This NOFO is preclinical and proof-of-concept focused. It is oriented toward translational readiness, not late-stage commercialization funding.

Can I submit multiple applications?

Yes, if scientifically distinct. NIH does not allow duplicates or highly overlapping applications under concurrent review.

Can I start with a simple concept then expand?

Concept-only proposals without a validated design pathway and development plan are at risk. Emphasize execution maturity and concrete milestones.

Why this opportunity matters for teams in the BRAIN ecosystem

For many research groups in neurotechnology, the funding gap is not funding for ideas; it is funding for reliable translational execution. This NOFO directly fills that gap by rewarding projects that can move from concept to preclinical proof with engineering discipline. That is why the NOFO’s emphasis on Gantt chart, needs assessment, design rationale, IP planning, and translational management matters as much as technical novelty.

It also aligns with companies, device-heavy labs, and translational teams that usually struggle to fit early-stage engineering into classic biology-led funding frameworks. If your team is serious about CNS-ready device development and has the team structure to execute, this NOFO can be a practical bridge.

Official links and next actions

• Official NOFO page (primary): https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-031.html
• ASSIST and NIH submission resources are linked from the NIH page
• Grants.gov Workspace: https://www.grants.gov/
• eRA Commons registration / system: https://public.era.nih.gov/

If you are in the final two months before deadline, focus on compliance quality first, then narrative polish. Reviewers will not reward unfinished innovation.